DHP-Frimal

DHP-Frimal

Manufacturer:

Mersifarma TM
Full Prescribing Info
Contents
Dihydroartemisinin 40 mg, piperaquine phosphate 320 mg
Indications/Uses
Treatment of uncomplicated malaria disease caused by P.falciparum and/or P.vivax malaria.
Dosage/Direction for Use
Day 1-3: ≥15 years, ≥60 kg 4 tab ≥15 years, 41-59 kg 3 tab 10-14 years, 31-40 kg 2 tab 5-9 years, 18-30 kg 1.5 tab 1-4 years, 11-17 kg 1 tab 2-11 months, 6-10 kg 0.5 tab 0-1 month, <5 kg 0.25 tab.
Contraindications
Hypersensitivity to dihydroartemisinin and piperaquine phosphate. Severe renal damage or liver disease. Blood disorders. Severe malaria according to WHO definition, drugs that prolong the QTc interval, symptomatic cardiac arrhythmias, severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction, electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia. Pregnancy.
Special Precautions
Hepatic and kidney function obstacle.
Adverse Reactions
Nausea, vomiting, stomachache, diarrhea and loss of appetite. Dizziness, headache, insomnia; allergic reaction eg rash, pruritus. Transient decrease of peripheral erythrocyte, transient increase of SGPT, SGOT and blood creatinine. Laboratory exam abnormalities.
Drug Interactions
Drugs that prolong the QTc interval.
MIMS Class
ATC Classification
P01BF05 - artenimol and piperaquine ; Belongs to the class of artemisinin and derivatives, combinations. Used in the management of malaria.
Presentation/Packing
FC tab 9's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in